Clinical trial
SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1
NCT00313937 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00313937 |
|---|---|
| Title | SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1 |
| Official title | Single Centre, Open, Controlled, Randomised (1:1), Parallel Group: Insulin Glargine vs. NPH: FPG (Fasting Plasma Glucose) in Patients With DM Type 1 Who Skip the Morning Meal During Treatment With MDI (Multiple Daily Injection) Basal/Bolus Insulin |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | Insulin glargine |
| Enrollment | 91 |
| Start date | Nov 1, 2001 |
| Primary completion | Jun 1, 2004 |
| First posted | Apr 12, 2006 |
| Last update posted | Dec 7, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: